<unk>  is a programmed death ligand-1 (PD-L1) blocking antibody that is FDA approved for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC) and patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.   Common adverse reactions include fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, rash, decreased appetite, and peripheral edema in patients with metastatic Merkel cell carcinoma. Most common adverse reactions in patients with locally advanced or metastatic urothelial carcinoma were fatigue, infusion-related reaction, musculoskeletal pain, nausea, decreased appetite, and urinary tract infection.
Avelumab
Nebacumab
Alirocumab
Burosumab
Evolocumab
Secukinumab
Durvalumab
Sarilumab